Coral Laboratories Profit & Loss Annual

BSE: 524506 | NSE: - | ISIN: INE683E01017 | Sector: Biotechnology & Drugs

547.90 +3.30 (0.61%)Updated : 14 Oct 2026

Research on

Interim Data

Annual Data

Fiscal Period	2026	2025	2024	2023
Period End Date	Mar 26	Mar 25	Mar 24	Mar 23
Total Operating Expense	72.13	91.18	69.21	76.01
Other Net	2.24	2.42	1.98	1.43
Diluted Weighted Average Shares	0.36	0.36	0.36	0.36
Depreciation/ Amortization	2.11	1.99	1.95	2.16
Operating Income	13.77	23.83	14.45	2.11
Net Income	16.38	24.16	15.79	6.45
Income Availableto Com Excl Extra Ord	16.38	24.16	15.79	6.45
Other Operating Expenses Total	5.79	4.48	2.99	3.13
Net Income Before Taxes	23.11	32.47	20.73	8.23
Interest Exp( Inc) Net- Operating Total	0.02	0.02	0.02	0.02
Net Income After Taxes	16.38	24.16	15.79	6.45
Income Availableto Com Incl Extra Ord	16.38	24.16	15.79	6.45
Costof Revenue Total	41.78	59.25	43.31	52.27
Gross Profit	44.12	55.76	40.35	25.85
Interest Inc( Exp) Net- Non- Op Total	7.10	6.23	4.31	4.68
Unusual Expense( Income)	-0.31	0.77	0.16	-0.04
Diluted Net Income	16.38	24.16	15.79	6.45
DPS- Common Stock Primary Issue	2.00	1.50	2.00	-
Provisionfor Income Taxes	6.73	8.31	4.94	1.78
period Type	-	-	-	-
Net Income Before Extra Items	16.38	24.16	15.79	6.45
Total Revenue	85.90	115.01	83.66	78.12
period Length	12.00	12.00	12.00	12.00
Revenue	85.90	115.01	83.66	78.12
Selling/ General/ Admin Expenses Total	22.74	24.68	20.77	18.47
Diluted Normalized EPS	45.23	69.22	44.54	17.96
Diluted EPS Excluding Extra Ord Items	45.85	67.61	44.19	18.04
Total Adjustmentsto Net Income	-	-	0.00	-